BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24623637)

  • 1. Adjunctive rifampicin may improve outcomes in Staphylococcus aureus bacteraemia: a systematic review.
    Russell CD; Lawson McLean A; Saunders C; Laurenson IF
    J Med Microbiol; 2014 Jun; 63(Pt 6):841-848. PubMed ID: 24623637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT.
    Thwaites GE; Scarborough M; Szubert A; Saramago Goncalves P; Soares M; Bostock J; Nsutebu E; Tilley R; Cunningham R; Greig J; Wyllie SA; Wilson P; Auckland C; Cairns J; Ward D; Lal P; Guleri A; Jenkins N; Sutton J; Wiselka M; Armando GR; Graham C; Chadwick PR; Barlow G; Gordon NC; Young B; Meisner S; McWhinney P; Price DA; Harvey D; Nayar D; Jeyaratnam D; Planche T; Minton J; Hudson F; Hopkins S; Williams J; Török ME; Llewelyn MJ; Edgeworth JD; Walker AS
    Health Technol Assess; 2018 Oct; 22(59):1-148. PubMed ID: 30382016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive rifampin for the treatment of Staphylococcus aureus bacteremia with deep infections: A meta-analysis.
    Ma H; Cheng J; Peng L; Gao Y; Zhang G; Luo Z
    PLoS One; 2020; 15(3):e0230383. PubMed ID: 32191760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of adjunctive rifampicin for treatment of Staphylococcus aureus bacteraemia: a systematic review and meta-analysis of randomized controlled trials.
    Dotel R; Gilbert GL; Hutabarat SN; Davis JS; O'Sullivan MVN
    J Antimicrob Chemother; 2023 Oct; 78(10):2419-2427. PubMed ID: 37583062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved outcome with early rifampicin combination treatment in methicillin-sensitive Staphylococcus aureus bacteraemia with a deep infection focus - a retrospective cohort study.
    Forsblom E; Ruotsalainen E; Järvinen A
    PLoS One; 2015; 10(4):e0122824. PubMed ID: 25874546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial.
    Thwaites G; Auckland C; Barlow G; Cunningham R; Davies G; Edgeworth J; Greig J; Hopkins S; Jeyaratnam D; Jenkins N; Llewelyn M; Meisner S; Nsutebu E; Planche T; Read RC; Scarborough M; Soares M; Tilley R; Török ME; Williams J; Wilson P; Wyllie S; Walker AS;
    Trials; 2012 Dec; 13():241. PubMed ID: 23249501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination antimicrobial therapy in patients with Staphylococcus aureus bacteraemia-a post hoc analysis in 964 prospectively evaluated patients.
    Rieg S; Joost I; Weiß V; Peyerl-Hoffmann G; Schneider C; Hellmich M; Seifert H; Kern WV; Kaasch A
    Clin Microbiol Infect; 2017 Jun; 23(6):406.e1-406.e8. PubMed ID: 27615722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial.
    Cheng MP; Lawandi A; Butler-Laporte G; Paquette K; Lee TC
    Trials; 2018 May; 19(1):297. PubMed ID: 29843781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of recurrence, early treatment failure and death from Staphylococcus aureus bacteraemia: Observational analyses within the ARREST trial.
    Szubert A; Bailey SL; Cooke GS; Peto T; Llewelyn MJ; Edgeworth JD; Walker AS; Thwaites GE;
    J Infect; 2019 Oct; 79(4):332-340. PubMed ID: 31398375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.
    Thwaites GE; Scarborough M; Szubert A; Nsutebu E; Tilley R; Greig J; Wyllie SA; Wilson P; Auckland C; Cairns J; Ward D; Lal P; Guleri A; Jenkins N; Sutton J; Wiselka M; Armando GR; Graham C; Chadwick PR; Barlow G; Gordon NC; Young B; Meisner S; McWhinney P; Price DA; Harvey D; Nayar D; Jeyaratnam D; Planche T; Minton J; Hudson F; Hopkins S; Williams J; Török ME; Llewelyn MJ; Edgeworth JD; Walker AS;
    Lancet; 2018 Feb; 391(10121):668-678. PubMed ID: 29249276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacteremia (SAB7): study protocol for a randomized controlled trial.
    Thorlacius-Ussing L; Andersen CØ; Frimodt-Møller N; Knudsen IJD; Lundgren J; Benfield TL
    Trials; 2019 May; 20(1):250. PubMed ID: 31046810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia.
    Weis S; Kesselmeier M; Davis JS; Morris AM; Lee S; Scherag A; Hagel S; Pletz MW
    Clin Microbiol Infect; 2019 Jul; 25(7):818-827. PubMed ID: 30928559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of an antimicrobial stewardship-led intervention for Staphylococcus aureus bacteraemia: a quasi-experimental study.
    Nguyen CT; Gandhi T; Chenoweth C; Lassiter J; Dela Pena J; Eschenauer G; Nagel JL
    J Antimicrob Chemother; 2015 Dec; 70(12):3390-6. PubMed ID: 26338049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of teicoplanin plus rifampicin in the treatment of bacteraemic infections caused by Staphylococcus aureus.
    Yzerman EP; Boelens HA; Vogel M; Verbrugh HA
    J Antimicrob Chemother; 1998 Aug; 42(2):233-9. PubMed ID: 9738842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and management of Staphylococcus aureus bacteraemia.
    Mitchell DH; Howden BP
    Intern Med J; 2005 Dec; 35 Suppl 2():S17-24. PubMed ID: 16271058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial.
    Kaasch AJ; Fätkenheuer G; Prinz-Langenohl R; Paulus U; Hellmich M; Weiß V; Jung N; Rieg S; Kern WV; Seifert H;
    Trials; 2015 Oct; 16():450. PubMed ID: 26452342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis.
    Kalil AC; Van Schooneveld TC; Fey PD; Rupp ME
    JAMA; 2014 Oct; 312(15):1552-64. PubMed ID: 25321910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with rifampicin or fosfomycin in patients with Staphylococcus aureus bloodstream infection at high risk for complications or relapse: results of a large prospective observational cohort.
    Rieg S; Ernst A; Peyerl-Hoffmann G; Joost I; Camp J; Hellmich M; Kern WV; Kaasch AJ; Seifert H
    J Antimicrob Chemother; 2020 Aug; 75(8):2282-2290. PubMed ID: 32355950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2017.
    Coombs GW; Daley DA; Lee YT; Pang S
    Commun Dis Intell (2018); 2019 Sep; 43():. PubMed ID: 31522665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients.
    Ruotsalainen E; Järvinen A; Koivula I; Kauma H; Rintala E; Lumio J; Kotilainen P; Vaara M; Nikoskelainen J; Valtonen V;
    J Intern Med; 2006 Feb; 259(2):179-90. PubMed ID: 16420547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.